Abstract | BACKGROUND: There is extensive epidemiological evidence that menopausal hormone therapy ( MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of therapies used by French women. Progestagen constituents, regimen (continuous or sequential treatment by the progestagen), and time interval between onset of menopause and start of MHT were examined. METHODS: We conducted a population-based case-control study in France in 1555 menopausal women (739 cases and 816 controls). Detailed information on MHT use was obtained during in-person interviews. Odds ratios and 95% confidence interval adjusted for breast cancer risk factors were calculated. RESULTS: CONCLUSION:
|
Authors | Emilie Cordina-Duverger, Thérèse Truong, Antoinette Anger, Marie Sanchez, Patrick Arveux, Pierre Kerbrat, Pascal Guénel |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 11
Pg. e78016
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 24223752
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Estrogens
- Progestins
- Receptors, Estrogen
- Receptors, Progesterone
|
Topics |
- Adult
- Aged
- Breast Neoplasms
(chemically induced, metabolism)
- Case-Control Studies
- Drug Administration Schedule
- Estrogen Replacement Therapy
(adverse effects)
- Estrogens
(adverse effects, therapeutic use)
- Female
- Humans
- Middle Aged
- Odds Ratio
- Postmenopause
- Progestins
(adverse effects, therapeutic use)
- Receptors, Estrogen
(metabolism)
- Receptors, Progesterone
(metabolism)
- Risk Factors
|